(CR-050) Evaluation of Topical Pravibismane in Moderately Infected Diabetic Foot Ulcers: Safety, Tolerability, and Efficacy Outcomes in an Exploratory Phase 2 Study
Friday, May 2, 2025
7:45 PM – 8:45 PM East Coast USA Time
Brett Baker, DC, MSc – Chief Innovation Officer, Microbion Corporation; Wayne Dankner, MD – Chief Medical Officer, Microbion Corporation; Carol Nelson, MBA – Program Manager, Microbion Corporation; Patrick Slaney, PhD – Project Manager, Microbion Corporation
This abstract will be presented on Friday, May 2, 2025 from 7:15PM to 7:45PM in room Texas A during the First to Podium Presentations and Founders and Abstract Award Ceremony session. Abstract content will be available Saturday, May 3, 2025.